Benchmark Upgrades Insulet Corporation (PODD) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Insulet Reports Fourth Quarter and Full Year 2015 Financial Results
February 25, 2016 4:01 PM ESTBILLERICA, Mass., Feb. 25, 2016 /PRNewswire/ -- Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System (OmniPod System), today announced financial results for the three months and full year ended December 31, 2015.       Â
Fourth Quarter Highlights and Recent Developments:
Fourth Quarter revenue of $100.1 million exceeds the Company's guidance of $86 to $96 million and represents year-over-year growth of 38%. U.S. OmniPod revenue up 21% to $52.9 million. International OmniPod revenue up 16% to $15.4 million. Drug Delivery revenue of $14.7 million (prior year was $0.8 million).... More